ABSTRACT
Peptide receptor radionuclide therapy (PRRT) is a nuclear medicine method that uses radionuclide-labeled somatostatin analogs (SSAs) to image and treat tumors overexpressing somatostatin receptor (SSTR). For the treatment of neuroendocrine tumors (NETs), PRRT alone can achieve a high disease control rate (DCR), but with a low disease response rate (DRR). Studies have shown that, PRRT combined with SSAs such as octreotide and lanreotide, PRRT combined with chemotherapy drugs such as 5-fluorouracil, capecitabine and temozolomide, PRRT combined with targeted drugs such as tarazopinib, everolimus and heat shock protein inhibitors, PRRT combined with immune drugs such as navumab, and the combination of 177Lu-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacceticacid (DOTA)-Tyr3-octreotide (TOC)/DOTA- D-Phe1-Tyr3-Thr8-octreotide (TATE) and 90Y-DOTATOC/DOTATATE, are promising to improve the efficacy of PRRT in the treatment of NETs with tolerable side effects. These PRRT combinations demonstrate an encouraging potential to improve clinical outcomes in NETs patients, and more prospective randomized clinical trials are needed to further validate current findings.
ABSTRACT
Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors leading to serious complications in the cardiovascular system. As somatostatin receptor (SSTR) is highly expressed in PPGL, SSTR-targeting imaging, particularly PET/CT based on 68Ga-labelled somatostatin analog represented by 68Ga-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid- D-Phe1-Tyr3-Thr8-octreotide (DOTATATE), becomes an important tool for location and assessment of systemic metastases. Treatments for metastatic PPGL are limited. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE provides a new therapeutic option for patients with inoperable PPGL and demonstrates satisfying efficacy. This article summarizes the advances of SSTR-targeting imaging and PRRT in the diagnosis and treatment of PPGL.
ABSTRACT
Objective To research the correlation of the expressions of lipocalin-2 (LCN-2) and its receptor (NGALR) in serum and placenta with preeclampsia.Methods From Dec.2010 to Apr.2011,64 women with preeclampsia who delivered in Affiliated Hospital of Qingdao University Medical College were recruited in the study,including 26 women with moderate preeclampsia ( MPE group) and 38 women with severe preeclampsia (SPE group).Twenty-five healthy pregnant women were taken as control group.LCN-2 and NGALR mRNA and protein expression in placenta were measured by reverse transcription-PCR ( RTPCR) and western blot,respectively.Results ( 1 ) The serum levels of LCN-2 in MPE group and SPE group [ (58 ±20),(90 ± 18) μg/L] were significantly higher than that in control group [ ( 19 ±6) μg/L,P＜0.01] ; the serum LCN-2 level in SPE group was significantly higher than that in MPE group (P ＜0.01).(2) LCN-2 mRNA expression in placenta in MPE group and SPE group (0.55 ±0.14,0.61 ±0.14) were both significantly higher than that in control group (0.28 ±0.16,P ＜0.01 ) ; LCN-2 protein expression in placenta of MPE group and SPE group ( 2.2 ± 0.4,2.4 ± 0.5 ) were also significantly higher than that in control group (1.4 ±0.4,P ＜0,01 ),no significant difference was found between MPE group and SPE group ( P ＞ 0.05 ),(3) No significant difference was found in the expressions of NGALR mRNA in placenta among MPE group,SPE group and control group (0.46 ±0.1l,0.46 ±0.14,0.45 ±0.15,P ＞0.05 ).(4) NGALR protein expressions in MPE group,SPE group and control group were 2.7 ±0.8,3.0 ±0.9,and 2.7 ± 0.9,and there were no significant difference among these three groups ( P ＞ 0.05 ).(5) In preeclampsia,serum LCN-2 level significant associated with 24 hours total urinary protein and uric acid ( r =0.565,0.476,P＜0.01).LCN-2 serum level were not associated with systolic pressure and diastolic pressure (P ＞ 0.05 ) ; there were no association with the expressions LCN-2 mRNA aud protein in placenta ( P ＞ 0.05).Conclusions Serum LCN-2 level is closely related to the progress of preeclampsia.Increasing expression of LCN-2 in placenta may be a compensatory response to preeclampsia.
ABSTRACT
Objective To study the location and level of relaxin receptor in placenta tissues of preeclampsia and normal pregnancy,and the relationship of relaxin receptor with pre-eclampsia.Methods Twenty-six placenta tissue samples from pregnant women with severe preeclampsia(study group),and 20samples from normal pregnancies(control group)were obtained.We detected the expression of relaxin receptor by immunohistochemistry and the expression of relaxin receptor mRNA by RT-PCR.Results In the placenta of control and preeclampsia groups,the leucine-rich repeat-containing G protein-coupled receptor(LGR7)was positively expressed.Relaxin receptor was located in the membrane of trophoblast cells.There were both strong signals on cytotrophoblastic cells and syneytiotrophoblast.The level of relaxin receptor in the control group was 0.912 ±0.003.and 0.625±0.037 in the preeclampsia group.Thedifference between the two groups was obvious(P＜0.01).In the control group,the level of relaxin receptor mRNA was 0.776±0.021;in the preeclampsia group,it was 0.393±0.075.The difference was obvious(P＜0.01).Conclusion Decrease in the expression of relaxin receptor at placenta is related with the occurrence and development of preeclampsia.